Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 3/20 | 0.48 |
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 2/20 | 0.47 |
| ▸ | MC5R | P33032 | 2/20 | 0.47 |
| ▸ | MC3R | P41968 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556817 | 0.86 | NLN (0.62) | OPRD1NLNDPP4HTR2AHTR2C | |
| SCHEMBL26605069 | 0.84 | OPRD1 (0.56) | OPRD1NLNDPP4HTR2AHTR2C | |
| SCHEMBL26605072 | 0.84 | OPRD1 (0.56) | OPRD1NLNDPP4HTR2AHTR2C | |
| SCHEMBL5558741 | 0.84 | CA12 (0.52) | OPRD1NLNDPP4MC4RMC5R | |
| SCHEMBL6019536 | 0.84 | CTSS (0.61) | OPRD1NLNDPP4HTR2AHTR2C | |
| SCHEMBL6047673 | 0.84 | MME (0.62) | MMEACECTSCALDH1A1HPGD | |
| SCHEMBL1329817 | 0.84 | MME (0.62) | MMEACECTSCALDH1A1HPGD | |
| SCHEMBL1329815 | 0.84 | MME (0.62) | MMEACECTSCALDH1A1HPGD | |
| SCHEMBL23142774 | 0.83 | OPRD1 (0.63) | OPRD1MMEACECPA1ACE2 | |
| SCHEMBL1769595 | 0.83 | NLN (0.50) | OPRD1NLNDPP4HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252693-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | NOVARTIS PHARMACEUTICALS CORPORATION | 2024-08-01 | — | — | US | disclosed |
| EP-4323017-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | Novartis AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-117083088-A | Folate receptor targeted radiotherapy agent and use thereof | 诺华股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| EP-4097120-A1 | ISOTOPICALLY LABELLED SELECTIVE CXCR4 BINDING PEPTIDE CONJUGATE AND METHODS FOR MAKING AND USING THE SAME | Mainline Biosciences LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2022219569-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | NOVARTIS AG (CH) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240252693-A1 | FOLATE RECEPTOR-TARGETED RADIOTHERAPEUTIC AGENTS AND THEIR USE | FOLR1, FOLR2, FOLH1 | OPRD1 4084/4885NLN 3301/4885DPP4 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.